GlassScriptPhysician profile
Talat Tayyaba
NPI 1467541664
$3,041.05
in general payments reported to CMS, 2019-2025
20 companies · $18.74 in 2025
The $18.74 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $300 · 2021: $735 · 2022: $982 · 2023: $784 · 2024: $15.89 · 2025: $18.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.39 | 2021-2024 | Vraylar |
| Tris Pharma INC | $517.17 | 2019-2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $312.98 | 2019-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $224.11 | 2021-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $199.44 | 2019-2023 | Jornay Pm |
| Corium, LLC | $170.05 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $151.93 | 2021-2023 | Rexulti |
| Eisai INC. | $144.85 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $113.43 | 2020-2023 | Spravato |
| Allergan, INC. | $104.33 | 2019-2020 | |
| Lundbeck LLC | $100.87 | 2022-2023 | Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.19 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $62.46 | 2022 | |
| Validus Pharmaceuticals LLC | $50.72 | 2022-2023 | Equetro |
| Shire North American Group INC | $40.59 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $30.45 | 2020 | |
| Alkermes, INC. | $30.08 | 2020 | |
| Neurocrine Biosciences, INC. | $25.61 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.66 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.74 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talat Tayyaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.